Co-Diagnostics, Inc. to Host Booth at CES 2023 January 5-8
01/05/2023 - 09:30 AM
SALT LAKE CITY Jan. 5, 2023 (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the 2023 Consumer Electronics Show (CES) this year from January 5-8 in Las Vegas, Nevada .
The Company will be exhibiting its upcoming Co-Dx PCR at-home and point-of-care platform, currently in the final stages of preparation for clinical evaluations prior to submission to the U.S. Food and Drug Administration for regulatory authorization. Attendees interested in learning more about the Company and its products are invited to visit Booth #8063 in the North Hall of the Las Vegas Convention Center.
The Co-Dx PCR platform is subject to FDA review and is not currently for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-ces-2023-january-5-8-301714315.html
SOURCE Co-Diagnostics
CODX Rankings
#5113 Ranked by Stock Gains
CODX Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Salt Lake City
About CODX
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
